DAM
SYRE icon

DLD Asset Management’s Spyre Therapeutics SYRE Stock Holding History

DLD Asset Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-30,000
Closed -$503K – 458
2025
Q3 		$503K Buy
+30,000
New +$489K 0.04% 214

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

DLD Asset Management's SYRE Position: Q4 2025 in Review

DLD Asset Management sold out of Spyre Therapeutics (SYRE) in Q4 2025, closing a stake of 30,000 shares — an estimated $503K sold.

DLD Asset Management first reported a position in SYRE in Q3 2025 and held it in 1 quarter. The position peaked at $503K in Q3 2025. 153 funds tracked by Wall St. Rank hold SYRE as of Q4 2025.

  • DLD Asset Management reported no remaining Spyre Therapeutics position as of Q4 2025 after selling out during the quarter.
  • DLD Asset Management sold 30,000 Spyre Therapeutics shares in Q4 2025, an estimated $503K.
  • DLD Asset Management first reported a position in Spyre Therapeutics in Q3 2025 and held it in 1 quarter.
  • DLD Asset Management's Spyre Therapeutics position peaked at $503K in Q3 2025.
  • 153 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q4 2025.

Based on DLD Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.